Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA
Articles
March 4th 2025
Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC
Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA Melody Chang, RPh, MBA, BCOP Nicholas Bouchard, PharmD Frank Scimeca, PharmD, MBA, BCOP
Experts discuss how they balance safety, efficacy, and overall patient prognosis when selecting third-line treatments for metastatic colorectal cancer (mCRC) and explore how the toxicity profiles of fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab differ, informing treatment decisions.
March 4th 2025
Treatment Options in mCRC: A Clinical Overview
Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA Melody Chang, RPh, MBA, BCOP Nicholas Bouchard, PharmD Frank Scimeca, PharmD, MBA, BCOP
Experts provide an overview of third-line treatment options for metastatic colorectal cancer (mCRC) in patients with disease progression through all available regimens, focusing on fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab.
Latest Updated Articles
Published: February 20th 2025 | Updated: February 21st 2025
Managed Care Reflections: Insights From Richard J. Gilfillan, MD; and Donald M. Berwick, MD, MPP
Published: January 16th 2025 | Updated: January 29th 2025
FDA Proposal Aims to Reduce Smoking Addiction and SCLC Cases
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
